Shanda Asset Management Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Shanda Asset Management Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$844K	–	36
2019 Q2	$844K	Hold	10,000	–	–	0.16%	20
2019 Q1	$881K	Hold	10,000	–	–	0.14%	37
2018 Q4	$714K	Hold	10,000	–	–	0.13%	37
2018 Q3	$1.23M	Hold	10,000	–	–	0.2%	22
2018 Q2	$982K	Hold	10,000	–	–	0.15%	34
2018 Q1	$829K	Hold	10,000	–	–	0.14%	26
2017 Q4	$776K	Hold	10,000	–	–	0.12%	33
2017 Q3	$613K	Hold	10,000	–	–	0.08%	33
2017 Q2	$460K	Hold	10,000	–	–	0.07%	28
2017 Q1	$433K	Hold	10,000	–	–	0.06%	30
2016 Q4	$387K	Hold	10,000	–	–	0.07%	24
2016 Q3	$506K	Buy	+10,000	New	+$498K	0.08%	21

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shanda Asset Management Holdings's NBIX Position: Q3 2019 in Review

Shanda Asset Management Holdings sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 10,000 shares — an estimated $844K sold.

Shanda Asset Management Holdings first reported a position in NBIX in Q3 2016 and held it in 12 quarters. The position peaked at $1.23M in Q3 2018. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

Shanda Asset Management Holdings reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
Shanda Asset Management Holdings sold 10,000 Neurocrine Biosciences shares in Q3 2019, an estimated $844K.
Shanda Asset Management Holdings first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 12 quarters.
Shanda Asset Management Holdings's Neurocrine Biosciences position peaked at $1.23M in Q3 2018.
332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.